Global Cancer Angiogenesis Inhibitors Market is segmented By Type (VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy, Matrix Degrading & Remodeling Targeted Therapy, Others), By Application (Cancer, Interferon Alpha-2α, Ocular Neovascularization), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Cancer Angiogenesis Inhibitors Market Overview
The Global Cancer Angiogenesis Inhibitors Market is expected to grow at a CAGR during the forecast period (2024-2031).
Angiogenesis is the development of new blood vessels. This process involves the migration, extension, and differentiation of endothelial cells, which line the interior wall of blood vessels. Cancer angiogenesis inhibitors are novel cancer-fighting agents because they block the growth of blood vessels that sustain tumor growth rather than blocking the growth of tumor cells themselves.
Cancer angiogenesis inhibitors prevent in several ways with various steps in blood vessel growth. Some are monoclonal antibodies that specifically identify and bind to VEGF. When VEGF is attached to these drugs, it is unable to initiate the VEGF receptor. Other angiogenesis inhibitors attach to VEGF and its receptor and other receptors on the surface of endothelial cells or other proteins in the downstream signalling pathways, blocking their activities. Some angiogenesis inhibitors are immunomodulatory drug agents that stimulate or suppress the immune system and have antiangiogenic properties.
Cancer Angiogenesis Inhibitors Market Summary
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Type, By Application, By End User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights - Request Free Sample
Cancer Angiogenesis Inhibitors Market Dynamics
The cancer angiogenesis inhibitors market growth is driven by the increasing burden of cancer, improving research and development investments, generates novel therapies and government initiatives to increase cancer awareness. The change in the current lifestyle has led to the exposure of a large population to certain risk factors that contribute to the cancer angiogenesis inhibitors market in the forecast period.
Increasing cancer cases across the world are driving the market growth
The increasing number of cancer cases such as breast cancer, prostate cancer, and lung cancer globally is expected to fuel the market's growth over the forecast period. As per the World Health Organization, in 2018, approximately 9.6 million deaths recorded over the globe were due to cancer. Furthermore, the National Cancer Institute prognosticated that in 2018, around 1,735,350 new cancer cases would be diagnosed in the US. Additionally, lung cancer is expected to increase the number of new cancer rate cases by 439.2 per 100,000 cases per year.
About 1.9 million new cancer cases and 693,000 cancer deaths were reported in 2018 in North America. Prostate cancers are the most generally diagnosed cancers amongst males in North America. However, breast cancer remains the leading cancer in females. As per the American Cancer Society estimates, breast cancer is the most prevalent type of cancer in the US as it caused morbidity in 234,087 people and led to 41,904 deaths in 2018.
Cancer usually develops in older people. 87% of all cancers in the United States are diagnosed in people 50 years or older. Certain behaviors also increase risk, such as eating an unhealthy diet or not being physically active. In the US, approximately 40 out of 100 men and 38 out of 100 women will develop cancer during their lifetime.
Because tumors cannot grow beyond a specific size or spread without a blood supply, scientists have developed drugs called angiogenesis inhibitors, blocking tumors. These drugs, also called antiangiogenic agents, aim to prevent or slow the growth of cancer by starving it of its needed blood supply. Thus growing cancer across the world is driving the market growth in the forecast period.
The improving research and development is driving the market growth
The rising research and development for new drugs to diagnose cancer are driving the market growth. To do this, researchers create and investigate new medications. Researchers also look for new ways to use medications that are previously available. Subsequent drugs are created, researchers examine them on human tumor cells in the lab. They see if the drugs stop the outgrowth of cancer cells in the human body. Next, they examine the drug in animals to determine if it is still capable of treating cancer. Researchers examine the drug in 2 or more animal classes. They also learn what side effects the medication may cause and what drug to test in people.
The U.S. Food and Drug Administration does not produce or test drugs. Alternatively, medical research universities, government agencies such as the NCI, and drug companies find and examine new drugs. The sponsor is the group that develops a drug. It does the research needed for the FDA to approve the drug.
Side Effects associated with drugs will hamper the market
Side effects associated with VEGF-targeting angiogenesis inhibitors can involve bleeding, clots in these arteries (with resultant stroke or heart attack), hypertension, damaged wound healing, reversible posterior leukoencephalopathy syndrome (a brain disorder), including protein in the urine. Gastrointestinal perforation and fistulas also seem to be rare side effects of some angiogenesis inhibitors.
Antiangiogenesis agents that target the VEGF receptor produce additional side effects, including biochemical hypothyroidism, hand-foot syndrome, fatigue, diarrhea, cardiac failure, and hair changes. These factors will hamper the market growth in the forecast period.
COVID-19 Impact Analysis
According to the CDC, the senior population with underlying severe therapeutic conditions, including people with cancer, might be at higher risk for severe illness from COVID-19. Patients with hepatocellular carcinoma are at higher risk for severe COVID-19.
According to a research article by Hidenori Toyoda et al., published in Hepatology Communications Journal 2020, during the COVID‐19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of chronic liver disease such as hepatocellular carcinoma (HCC). Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19.
Cancer Angiogenesis Inhibitors Market Segment Analysis
By type, the cancer angiogenesis inhibitors market is classified into vegf targeted therapy, fgf targeted therapies, oncogene targeted therapy, matrix-degrading & remodelling targeted therapy, others.
VEGF targeted therapy segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
VEGF Targeted therapy mediates numerous changes within the tumor vasculature, including endothelial cell proliferation, migration, invasion, survival, chemotaxis of bone marrow-derived progenitor cells, vascular permeability and vasodilation.
Several approaches to inhibiting VEGF signalling include neutralizing the ligand or receptor by antibodies and blocking VEGF receptor (VEGFR) activation and signalling with tyrosine kinase inhibitors. VEGF-targeted therapy is efficacious as a single agent in renal cell carcinoma and hepatocellular carcinoma. In contrast, it is only beneficial when combined with chemotherapy for patients with metastatic colorectal, non-small-cell lung and metastatic breast cancer.
VEGF-targeted therapy affects numerous cell types within the tumor microenvironment, including endothelial cells, hematopoietic progenitor cells, dendritic cells and tumor cells. It has multiple mechanisms of action that might be dependent on tumor type. VEGF-targeted therapy affects vascular function (flow and permeability) and blocks further new blood vessel growth.
Several vascular endothelial growth factors (VEGF)-targeted agents, administered either as single agents or combined with chemotherapy, have been shown to benefit patients with advanced-stage malignancies. VEGF-targeted therapies were initially developed with the notion that they would inhibit new blood vessel growth and thus starve tumors of necessary oxygen and nutrients. However, it has become increasingly apparent that the therapeutic benefit associated with VEGF-targeted therapy is complex and probably involves multiple mechanisms. A better understanding of these mechanisms will lead to future advances in using these agents in the clinic.
Cancer Angiogenesis Inhibitors Market Geographical Share
North America region holds the largest market share in the global cancer angiogenesis inhibitors market
North America region is dominating the global cancer angiogenesis inhibitors market accounted for the largest market share in 2020, owing to the growing incidence of cancer in the country, the presence of key market players, and the launch of new commodities influence market growth in the region.
The U.S. Food and Drug Administration (FDA) has approved a number of angiogenesis inhibitors to treat cancer. Most of these are targeted therapies that were developed specifically to target VEGF, its receptor, or other specific molecules involved in angiogenesis.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period due to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and effective treatment in emerging countries, such as China and India.
Cancer Angiogenesis Inhibitors Market Companies and Competitive Landscape
The cancer angiogenesis inhibitors market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen, Pfizer Inc., Acceleron Pharma, Advenchen Laboratories, Allergan, Alnylam Pharmaceuticals, Amgen, Angstrom Pharmaceuticals, Biocon, Bionomics, CASI Pharmaceuticals, Celgene Corporation, Enzon Pharmaceuticals among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Cancer Angiogenesis Inhibitors Market globally.
Amgen Inc.
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
Product Portfolio: The Company’s portfolio is comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Why Purchase the Report?
- Visualize the composition of the cancer angiogenesis inhibitors market segmentation by type, application, and end-user highlighting the key commercial assets and players.
- Identify commercial opportunities in the cancer angiogenesis inhibitors Market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of cancer angiogenesis inhibitors market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global cancer angiogenesis inhibitors market report would provide access to an approx. 61 market data table, 64 figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
